Logo image
利用電腦虛擬高速篩選與藥效基團評分來尋找抑制酪氨酸去磷酸酶的第二型糖尿病先導藥物
Thesis

利用電腦虛擬高速篩選與藥效基團評分來尋找抑制酪氨酸去磷酸酶的第二型糖尿病先導藥物

劉俊呈
Masters, 國立清華大學, 分子醫學研究所
2004

Abstract

第二型糖尿病 酪氨酸去磷酸酶 藥效基團 CATALYST軟體 DOCK軟體 Type II Diabetes Protein Tyrosine Phosphatase 1B PHARMACOPHORE CATALYST PROGRAM DOCK PROGRAM
The research on the knock-out studies in mice manifests that the insulin resistance in those mice lacking for PTP1B protein would evidently increases and possesses the certain resistivity against obesity. Consequently, PTP1B is considered as the target for medicine designed to treat for Type II diabetes. With the progress in computational science, it is gradually becoming a trend to utilize the virtual screening method to accelerate the R&D in medication and effectively shorten the time and expense of R & D. In fact, there are not a few successful examples applied in foreign pharmacists. This experiment is in regard to adopting direct and indirect drug methods to screen the available inhibitor for PTP1B. First, it’s to find out the reasonable parameter computed through “DOCK” software of direct drug method towards the PTP1B receptor, the model based on the aforementioned parameter, which correlation can reach 0.79 in the activity ranks of inhibitor, then to proceed the virtual screening in “Maybridge” chemistry database. On the other hand, to establish the pharmacoophore which the so-called “Catalyst” indirect drug method software applied in screening PTP1B inhibitor, then reaching 0.976 correlation and 0.868 rms following this step, to make the activity predict on the compound screened by the DOCK software. In addition to this, assorting with two scoring function in terms of XScore and PScore, and the screening method of hydrogen bond, at last select 165 most potential lead compounds of PTP1B.

Metrics

1 Record Views

Details

Logo image